Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 4;7:1469. doi: 10.1038/s41598-017-01624-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

CpG methylome and transcriptome differences between cisplatin sensitive and resistant ovarian cancer lines. DNA methylomes of the cells sensitive or resistant to cisplatin were profiled with Reduced Representation Bisulfite Sequencing and transcriptomes with mRNA-sequencing. In (a) are the CpG sites with coverage ≥ 10 and minimum methylation difference of 20% (qval ≤ 0.05) in M019i cells, (see also Supplementary Table S1), (b) the distribution of differentially methylated cites in genomic regions, (c) distance of the differentially methylated sited from the closest transcription start sites, (d) the transcriptome differences (minimum absolute FC = 1.5, FDR ≤ 0.05) between cisplatin sensitive and resistant ovarian cancer cells (M019i), (e–h) qRT-PCR validation of AKR1C1, CYP4F11, CYP24A1, MIR205HG, and SLC6A14 differences in M019i and OC001 cells (y-axis: relative expression level).